MP Advisors is an independent company offering research and paramount knowledge within a healthcare industry. At present great many global pharmaceutical companies, especially in U.S., Europe, Russia, India and Japan are among MP Advisors’s clients. When founded, 1996, the agency is ensuring investment solutions and assessing investment opportunities with a penetrating eye on risks and benefits from funding pharma manufacturing.
MP Advisors unparalleled service includes:
- Financial Analysis;
- Competitive landscaping;
- Macro Analysis;
- Technology Transfer;
- Mergers & Acquisitions;
- Strategic planning;
- Forecast.
Customized reports are in the focus area of skillful and competent experts who explore, analyze and interpret data, select tools and approaches on how efficiently reach ultimate market decisions and reach maximum understanding of current biotech and therapeutic issues.
More than 200 medical companies’ profiles are in its database. MP Advisors publishes insightful reports fortified by proficient views of key specialists. Moreover, it produces ad hoc reports on Japan and Indian generic drug, Para IV, oncology, obesity and other therapy reviews.
Publications found:
456
Sort by:
Eisai, Belviq Approval – Implications on Eisai’s Bottom Line is Weak!
US$ 90.00
We continue with our Underperform rating on Eisai following approval of Belviq (lorcaserin, 5 HT 2C agonist, partnered with Arena) in the US. Despite ... (Qnexa has PDUFA date on 26th July 2012; we are expecting approval). Belviq administration is to be discontinued if 5% weight loss is not achieved within 12 ...
June 2012
3 pages
Astellas, Mirabegron PDUFA on 29th – Doubts Prevail Over Favorable Outcome!
US$ 90.00
We are skeptical if the FDA will approve Mirabegron (first in class β3-AR agonist, overactive bladder ... the fact that CV risk concerns raised with Mirabegron are mild in nature and the FDA’s ... seems to be more common view of street - we expect mirabegron to generate $300m revenue by 2016 from USA; our WW peak ...
June 2012
3 pages
Onyx Pharma – Kyprolis to Accelerate Growth
US$ 140.00
... events – cardiovascular toxicities and deaths associated with Kyprolis as expected. ONXX has finally succeeded in ... Nexavar (L, RCC, HCC, partnered with Bayer), Kyprolis, and Regorafenib (R, oral multi-kinase inhibitor, GIST ... on Jun 21, 2012 on Onyx Pharma titled “Onyx Pharma - Kyprolis to Accelerate Growth”
June 2012
4 pages
Rising Stars (Small-Mid Cap) Biotech/Biopharma: Investment Opportunities
US$ 400.00
... continue in 2012. In this report, we highlight the investment opportunities in the mid-small cap Rising Star companies: ARQL: Key Driver is Tivantinib (c-MET inhibitor) in PhIII for ... of the risk reward please read our report titled, “Rising Stars (Small-Mid Cap) Biotech/Biopharma: Investment Opportunities”.
June 2012
18 pages
ADA-2012 – UPDATE on SGLT2/1 inhibitors - Canagliflozin Rocks!
US$ 140.00
A relative assessment of new clinical data published on SGLT2 inhibitors at ADA 2012, suggests that JNJ/Mitsubishi Tanabe’s canagliflozin is all set to ... pipeline candidates with a differentiated clinical profile include Lexicon’s dual SGLT2/1 inhibitor – LX4211 - Superior post prandial glucose reduction, ...
June 2012
5 pages
Celgene: Long-Term Prospects Intact but Competition Emerging!
US$ 140.00
... flat growth of Revlimid (L, RRMM, MDS), reported in its 1Q12, we expect Celgene (CELG) to meet its FY12 guidance (Total rev.: $5.4-$5.6b and EPS ... , please read our report, released on 12th June on CELG, titled “Long-Term Prospects Intact but Competition Emerging!”
June 2012
3 pages
Sanofi, ORIGIN TRIAL – No Implications, but removes the cancer risk overhang
US$ 90.00
The ORIGIN trial was intended to expand Lantus use in the ... existing use in the late stage setting. In the trial, Lantus did delay the progression of pre-diabetes to diabetes ... disadvantage. The only positive implication for Lantus from the ORIGIN trial is that it completely removes the cancer risk overhang on ...
June 2012
2 pages
The European League Against Rheumatism (EULAR) 2012 Noteworthy Takeaways
US$ 140.00
Among all oral options for the treatment of Rheumatoid Arthritis (RA), JAK inhibitors are ready to reach the market but the debate will continue – whether targeting specific JAK-1, 2, &3 or a multipronged approach like JAK 1/2, 1/3 is better? JAK1 may be the most suitable target as an anti-inflammatory drug ...
June 2012
10 pages
ELAN- A Tale of Two: Tysabri = Support; Bapineuzumab = Upside
US$ 300.00
... REMS program for PML risk have driven and anchored Elan Corp.'s (ELN), but future growth is highly dependant on the success ... , Please read our report released on June 11, 2012 on ELN, titled “A Tale of Two: Tysabri = Support; Bapineuzumab = Upside”.
June 2012
12 pages
VERTEX PHARMA - Time to Book Profits
US$ 140.00
Vertex (VRTX) has evolved from an innovator to a profitable Biotech but at the ... detail, please read our report released on 11th June, 2012 on Vertex titled “Time to Book Profits….!”
June 2012
4 pages
Prioritizing Generic Drug development pipeline – The top Fifty Opportunities
US$ 5,000.00
... crucial aspects of growth strategy for a generic company or an Active Pharmaceutical Ingredient manufacturing ... recently approved or are in late stage development / Filed but with significantly success probability ... / therapeutic value compared to marketed drugs Anticipated competition in the therapy and ...
June 2012
100 pages
Novartis, ACZ885 – Impressive data in SJIA, but no meaningful commercial opportunity
US$ 90.00
Novartis today reported positive Phase 3 data on ACZ885 (canakinumab) in SJIA. The data is impressive but commercial opportunity would be limited as SJIA is a rare disease, while ... 20000 or less depending on the weight. While if NVS chose to price ACZ885 at its existing annual cost ($100,000), it may not be able ...
June 2012
1 pages
Biogen: Teriflunomide Does Not TOWER Over BG-12!
US$ 90.00
Top-line data from PhIII trial, TOWER of Sanofi’s Aubagio (teriflunomide, R, RRMS, PDUFA: 3Q12) reaffirms our take on BG-12 (Dimethyl fumerate, R, Est. ... details, please read our report released on June 1st , 2012 on Biogen (BIIB), titled “Teriflunomide Does Not TOWER Over BG-12”
May 2012
4 pages
SUN PHARMA: Strong Quarter and Brighter Outlook
US$ 140.00
We reiterate Sun Pharma as our Top Pick in the Indian pharma space after its higher ... growth like (1) continuing sales of Doxil generic after Sun gets ANDA approval (2) launch of Prandin, Comtan ... In addition to the near term drivers, we see Sun Pharma positioning itself to become a leader in global generics with ...
May 2012
7 pages
IPCA- Ready to Fire from All Directions
US$ 140.00
IPCA’s Q4 FY12 result was slightly below our ... on Q-o-Q basis mainly due to the reduction in production as IPCA implemented the track and trace system in its manufacturing facility ... margin of 5%) too impacted the business. We remain enthused about Ipca’s 18-20% growth guidance for domestic pharma in FY13. We rate ...
May 2012
7 pages
ASTELLAS - Enzalutamide Filed in the US - A ‘Priority Review’ is Likely!
US$ 90.00
... review will be due within 60 days from the filing date, i.e. May 23rd. Enzalutamide is the first in class androgen receptor signaling inhibitor ... data is better for enzalutamide - 4.8 months vs. 3.9 months for Zytiga. Despite enzalutamide’s solid data, we find a limited bottom line impact on Astellas due to its ...
May 2012
3 pages
AMGEN: Innovation + Emerging Market – A Balanced Approach!
US$ 140.00
... boosted Amgen’s (AMGN) pipeline, while Mustafa Nevzat pharma (MN pharma, pvt., Turkey) is a strategic move to increase its presence in the growing emerging/ international markets ... read our report released on May 29th, 2012 on AMGN, titled “Innovation + Emerging Market – A Balanced Approach”
May 2012
7 pages
CIPLA - Nothing New – As Expected
US$ 140.00
... ‘rationalization’ of various partnerships in different geographies. Launch of Dymista and Vancomycin by Cipla’s partners in US too may not fetch any meaningful upside in the ... near term. We reiterate our Market Perform on Cipla but change our target price to `341 as we rollover to FY13 ...
May 2012
7 pages
REGENERON - Diversified Pipeline can Buffer the Setback
US$ 140.00
Despite the setback in the pipeline – negative recommendation from FDA advisory committee on ... franchise should be able to buffer some setbacks in the pipeline. The FDA advisory panel voted 11-0 against approval of the ... , released on May 14, 2012 on REGN, titled “Diversified Pipeline can Buffer the Setback”.
May 2012
6 pages
CADILA HEALTHCARE - Nearing Inflection Point
US$ 140.00
Cadila’s Q4 FY12 result was much higher than our estimates owing to ... declined by 4.5% due to forex loss. FY12 remained a year of consolidation after Cadila acquired Nesher, Bremer and Biochem. Going forward, the company ...
May 2012
8 pages
INCYTE: JAKAFI / JAKAVI to Drive Sustainable Profitability
US$ 140.00
Incyte (INCY) reported net revenues of $19.3m of the only approved drug for Myelofribrosis (MF), JAKAFI / JAKAVI (ruxolitinib, JAK 1/2 inhibitor, PhII/III in PV/ET; partnered with Novartis for ... , please read our report released on May 2, 2012 on INCY, titled “JAKAFI / JAKAVI to Drive Sustainable Profitability”
May 2012
3 pages
BIOCON, Exposed To Statin Hit and R&D Expenses
US$ 140.00
The increase in sales is because of high growth in Insulin sales in India (probably due to Pfizer’s marketing) and also growth in immunosuppressant sales. ...
April 2012
7 pages
CELGENE – Revlimid Sales Disappoints, but Long Term Prospects Intact!
US$ 90.00
Though Q1’12 earnings were disappointing (flat growth of Revlimid), we expect Celgene (CELG) should able to meet its FY12 guidance (Total rev.: $5.4-$5.6b ... read our report released on 27th April, 2012 on CELG titled, “Revlimid Sales Disappoints, but Long Term Prospects Intact!”
April 2012
4 pages
ALEXION: Soliris’ Label Expansion & Diversification to Perk ALXN Up!
US$ 140.00
... Hemolytic Uremic Syndrome (aHUS) indication, and label expansion in other rare and high unmet need indications of Soliris; we expect the growth trajectory continues ... , please read our report released on April 25, 2012 on ALXN, titled “Soliris’ Label Expansion & Diversification to Perk ALXN Up!”
April 2012
5 pages